FOLD — Amicus Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $3.13bn
- $3.24bn
- $399.36m
- 49
- 14
- 48
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -356 | -277 | -250 | -237 | -152 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 91 | 66.9 | 70.7 | 105 | 128 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 11.6 | -32.1 | -28.9 | -39.9 | -48 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -250 | -233 | -202 | -167 | -69.1 |
Capital Expenditures | -20 | -3.23 | -3.88 | -3.77 | -7.44 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 115 | -10.4 | 82.6 | 96.1 | 106 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 95.2 | -13.6 | 78.8 | 92.3 | 98.1 |
Financing Cash Flow Items | 16.6 | -10 | -16.7 | -11.5 | -20.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 218 | 263 | 212 | -7.46 | 61.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 64 | 19.8 | 83.3 | -96.3 | 97 |